Large-scale testing (Phase 3)Study completedNCT01973218
What this trial is testing
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
Who this might be right for
Meningococcal Disease
Novartis Vaccines 264